Irrfan's spokesperson refutes reports of him undergoing ayurvedic treatment


(MENAFN- NewsBytes)

Irrfan's spokesperson refutes reports of him undergoing ayurvedic treatment
24 Mar 2018


Irrfan Khan is currently in the United Kingdom for the treatment of his disease which is Neuroendocrine Tumour.

Several reports stated that the actor has consulted Dr. Vaidya Balendu Prakash and is undergoing ayurvedic treatment.

However, his spokesperson has issued a clarification refuting all such reports.

He even slammed the media houses for misconstruing facts regarding Irrfan's illness for the sake of publicity.


Here's what Irrfan's spokesperson said
Fact


"As suggested by recent news reports, Mr. Khan is not consulting with Vaidya Balendu Prakash. It is unacceptable to be using someone's illness for your own publicity. We all need to respect the space asked for and wait for him or his wife's next statement," he added.


Irrfan revealed his disease on Twitter
Details


On March 5, Irrfan had shared that he is suffering from a "rare disease" and promised to divulge more information soon.

Days later, he revealed that the disease is Neuroendocrine Tumour, which made his fandom restless as to whether the actor will be able to recover or not.

Experts have said that Irrfan's tumour can be cured through timely surgery.


Meanwhile, his next 'Blackmail' is up for release
On the work front


Irrfan will be next seen on the big screen in Abhinay Deo's 'Blackmail'.

Also starring Kirti Kulhari, Arunodoy Singh, Divya Dutta, Pradhuman Singh, the film is slated to release on April 6.

The makers wanted to postpone the release pertaining to Irrfan's illness but he encouraged them to not delay the film.

MENAFN2403201801650000ID1096646643


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.